Evidence map›Paper›PMID 34535597›Full record

ArticleNephron2022

Limitations of SARC-F as a Screening Tool for Sarcopenia in Patients on Hemodialysis.

Keigo Imamura, Shohei Yamamoto, Yuta Suzuki, Ryota Matsuzawa, Manae Harada, Shun Yoshikoshi, Atsushi Yoshida, Atsuhiko Matsunaga

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nephron, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Keigo ImamuraDepartment of Rehabilitation Sciences, Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan, ap14306@st.kitasato-u.ac.jp.
Shohei YamamotoDepartment of Rehabilitation Sciences, Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan.
Yuta SuzukiDepartment of Rehabilitation Sciences, Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan.
Ryota MatsuzawaDepartment of Physical Therapy, School of Rehabilitation, Hyogo University of Health Sciences, Kobe, Japan.
Manae HaradaDepartment of Rehabilitation, Sagami Circulatory Organ Clinic, Sagamihara, Japan.
Shun YoshikoshiDepartment of Rehabilitation Sciences, Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan.
Atsushi YoshidaDepartment of Hemodialysis Center, Sagami Circulatory Organ Clinic, Sagamihara, Japan.
Atsuhiko MatsunagaDepartment of Rehabilitation Sciences, Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan.
Kitasato University · JPHyogo University of Health Sciences · JPNational Center for Global Health and Medicine · JPNational Institute of Public Health · JPNational Sagamihara Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThere are limited screening tools for sarcopenia in patients undergoing hemodialysis. This study aimed to investigate the reliability and validity of the SARC-F (Strength, Assistance in walking, Rise from a chair, Climb stairs, and Falls) questionnaire as a screening tool for sarcopenia (defined by the Asian Working Group for Sarcopenia [AWGS2019]) in patients undergoing hemodialysis.

methodsThis cross-sectional study enrolled 179 patients (mean age: 66.5 ± 12 years, 58% men) undergoing maintenance hemodialysis 3 times per week at a hemodialysis center in Japan. The SARC-F score, handgrip strength, usual gait speed, sit-to-stand test time, short physical performance battery (SPPB), and appendicular skeletal muscle mass were evaluated. The reliability and validity of the SARC-F were analyzed using receiver-operating characteristic curve, area under the curve (AUC), and sensitivity/specificity analyses.

resultsThere were 49 (27.4%) patients with sarcopenia. Patients with SARC-F ≥4 (59 patients, 33.0%) had poorer grip strength, lower SPPB score, and slower gait speed than those with SARC-F <4, while the skeletal muscle mass index did not differ significantly between the two groups. The sensitivity and specificity values of the SARC-F for identifying sarcopenia were 42.9% and 70.8%, respectively, while those for identifying severe sarcopenia were 66.7% and 72.3%, respectively. The AUCs of SARC-F were 0.57 for sarcopenia and 0.70 for severe sarcopenia. DISCUSSION/

conclusionThe SARC-F alone is an inadequate screening tool for sarcopenia in patients undergoing hemodialysis. It should be used in combination with objective assessment measures, rather than as a first-step screening tool, to diagnose sarcopenia.

Indexed as

AgedCross-Sectional StudiesFemaleHumansMaleMiddle AgedMuscle StrengthRenal DialysisReproducibility of ResultsSarcopeniaSensitivity and SpecificitySurveys and QuestionnairesHemodialysisJapaneseSARC-FSarcopeniaScreening

Identifiers

PMID34535597
PMCPMC8820431
OpenAlexW3199372368

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.